| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://zenotechlab.com | |
| Market Cap | 322.24 Cr. | |
| Enterprise Value(EV) | 328.24 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 3.63 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 14.53 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.96 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 11.57 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 4.56 | Calculated using Price: 52.80 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 6.10 Cr. | 61,030,568 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world. The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy. Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells. Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets. Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets. Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies. Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery. Product range of the company includes: Generics -- Biological
Chemical
New biologicals Zenotech develops new biological entities in the areas of
|
||
Company Profile
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.
The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.
Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.
Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.
Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.
Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.
Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.
Product range of the company includes:
Generics -- Biological
Chemical
New biologicals Zenotech develops new biological entities in the areas of
| 1 Day |
|
-2.22% |
| 1 Week |
|
+6.77% |
| 1 Month |
|
-8.89% |
| 3 Month |
|
-2.13% |
| 6 Month |
|
+30.53% |
| 1 Year |
|
+24.24% |
| 2 Year |
|
+153.24% |
| 5 Year |
|
+1.15% |
| 10 Year |
|
+84.23% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | -65.67 | -155.73 | -7.73 | 24.35 | -2.48 | |||||
| Return on Capital Employed (%) | -48.47 | -39.28 | -61.52 | -65.68 | -61.88 | -5.95 | 18.32 | 0.48 | ||
| Return on Assets (%) | -37.69 | -33.32 | -45.43 | -32.82 | -38.33 | -17.89 | -3.76 | 12.67 | -1.42 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 26 | 3 | -27 | -46 | -66 | 42 | 39 | 50 | 48 | 71 | |
| Non Curr. Liab. | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | -4 | |
| Curr. Liab. | 40 | 66 | 91 | 99 | 116 | 39 | 45 | 35 | 15 | 16 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 67 | 70 | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 82 | |
| Non Curr. Assets | 62 | 59 | 55 | 50 | 49 | 50 | 65 | 80 | 79 | 74 | |
| Curr. Assets | 5 | 11 | 8 | 3 | 2 | 31 | 19 | 6 | 7 | 7 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 67 | 70 | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 82 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 3 | 3 | 4 | 2 | 2 | 11 | 13 | 26 | 22 | 37 | |
| Other Income | 0 | 3 | 0 | 0 | 0 | 2 | 5 | 1 | 0 | 1 | |
| Total Income | 3 | 5 | 4 | 2 | 2 | 14 | 18 | 27 | 23 | 37 | |
| Total Expenditure | -24 | -20 | -24 | -10 | -13 | -19 | -17 | -17 | -16 | -19 | |
| PBIDT | -21 | -15 | -20 | -8 | -10 | -6 | 1 | 10 | 7 | 18 | |
| Interest | -1 | -5 | -7 | -8 | -8 | -2 | 0 | -1 | -2 | -1 | |
| Depreciation | -4 | -4 | -4 | -4 | -4 | -4 | -4 | -5 | -6 | -7 | |
| Taxation | 12 | ||||||||||
| Exceptional Items | 2 | 6 | |||||||||
| PAT | -26 | -23 | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 22 | |
| Adjusted EPS | -7 | -6 | -8 | -5 | -5 | -2 | -1 | 2 | 0 | 4 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | -10 | -24 | -8 | -5 | 2 | -16 | -14 | 11 | 6 | |
| Cash Fr. Inv. | 0 | 0 | -1 | 0 | 6 | -1 | -3 | -16 | -21 | -5 | |
| Cash Fr. Finan. | 2 | 10 | 30 | 7 | -1 | -1 | 47 | 15 | -3 | 0 | |
| Net Change | 0 | 0 | 5 | -1 | 0 | 0 | 28 | -15 | -12 | 1 | |
| Cash & Cash Eqvt | 2 | 2 | 6 | 6 | 0 | 0 | 28 | 13 | 1 | 2 |
|
Fri, 29 Apr 2022
Compliance Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Financial Year Ended March 31 2022 With reference to the subject please find enclosed herewith the Certificate issued by Mr. Mahadev Tirunagari Company Secretary in Practice Hyderabad in terms of regulation cited above for the financial year ended March 31 2022. |
|
Fri, 29 Apr 2022
Submission Of Standalone Audited Financial Results Of Zenotech Laboratories Limited (The Company) For The Fourth Quarter And Financial Year Ended March 31 2022 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we enclose herewith the following:1) the Standalone Audited Financial Results of the Company for the fourth quarter and financial year ended March 31 2022 together with the Report of Auditors on the said Results duly approved and taken on record by the Board of Directors of the Company at their meeting held today i.e. April 29 2022; and2) Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The meeting of the Board of Directors commenced at 5:50 PM and concluded at 8:30 PM. |
|
Fri, 29 Apr 2022
Intimation Pursuant To Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 We would like to inform that Board of Directors of Zenotech Laboratories Limited (the Company) in their meeting held today i.e. on April 29 2022 have considered and approved the request received from Daiichi Sankyo Company Limited (Daiichi) for reclassification from Promoter to Public Category.Please note that currently Daiichi does not hold any shares in the Company and the reclassification will not impact the overall promoter holding in the Company.The Company shall seek shareholders approval for the reclassification in line with the provisions ofRegulation 31A of SEBI Listing Regulations.As required under SEBI Listing Regulations we also enclosed herewith as an Annexure - Extract of the minutes of Board Meeting for your perusal.Request you to kindly take the same on record and oblige. |
| Wed, 18 May 2022 |
High Decrease 1 Month
|
High Increase 6 Months
|
High Increase 2 Years
|
Closing Near 200 SMA
|
Bearish Engulfing
|
Equities
M.F.
Sectors